Second Quarter 2026
Filed Aug 13, 2026Second Quarter 2026 Revenue of $1.3 Million, a 127% Increase Compared to Prior Year; Second Quarter Gross Profit of $0.8 Million, a 232% Increase Compared to Prior Year; Gross Margin of 64%
Revenue, gross profit and gross margin improved sharply year over year, supported by higher surgical procedures and SImmetry®+ revenue, but the company reported a $4.1 million net loss, held $1.7 million of cash and cash equivalents at quarter end, and stated that there can be no assurance it will repay or refinance its convertible notes in full.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $1.3 million | – | 127% |
| Gross profitGAAP | $0.8 million | – | 232% |
| Gross marginGAAP | 64% | – | a twenty-one percentage point improvement |
| Operating expensesGAAP | $4.2 million | – | – |
| Research and development expenseGAAP | 768 (In thousands) | – | – |
| Sales and marketing expenseGAAP | 1,869 (In thousands) | – | – |
| General and administrative expenseGAAP | 1,531 (In thousands) | – | – |
| Loss from operationsGAAP | (3,354) (In thousands) | – | – |
| Interest expenseGAAP | (852) (In thousands) | – | – |
| Net loss and comprehensive lossGAAP | $4.1 million | – | – |
| Net loss per share of common stock, basic and dilutedGAAP | $12.35 per share | – | – |
| Weighted-average shares of common stock outstanding, basic and dilutedGAAP | 328 (In thousands) | – | – |
| Revenue, six months ended June 30GAAP | $2.7 million | – | 106% |
| Gross profit, six months ended June 30GAAP | $1.8 million | – | – |
| Gross margin, six months ended June 30GAAP | 66% | – | – |
| Operating expenses, six months ended June 30GAAP | $8.4 million | – | – |
| Loss from operations, six months ended June 30GAAP | (6,634) (In thousands) | – | – |
| Net loss and comprehensive loss, six months ended June 30GAAP | $7.5 million | – | – |
| Net loss per share of common stock, basic and diluted, six months ended June 30GAAP | $23.16 per share | – | – |
What drove it
- The increase in quarterly revenue was primarily due to a significant increase in the number of surgical procedures, including the addition of revenue related to the SImmetry®+ System.
- The twenty-one point gross margin improvement was primarily driven by higher revenue and lower fixed costs, driving further absorption of production overhead costs within cost of goods sold.
- Operating expense growth was primarily due to higher sales expenses associated with higher revenue, the expanded commercial team and ongoing rollout of the SImmetry®+ System, as well as higher research and development expenses for future product additions.
- In July 2026, the Company recorded its highest monthly surgical case volume to date, following a 98% increase in physician and distributor training events in the first half of 2026 compared to the second half of 2025.
- On July 2, 2026, the Company announced U.S. Food and Drug Administration 510(k) clearance for the Catamaran® SI Joint Fusion System, including instrument upgrades and the reclassification of certain instruments from disposable to reusable status.
Concerns
- Net loss was $4.1 million, compared to a net loss of $2.8 million in the second quarter of 2025.
- The year-over-year increase in quarterly net loss was largely driven below the line by non-cash interest expense of $0.9 million, including amortization of the original issue discount related to convertible notes.
- Cash and cash equivalents were $1.7 million as of June 30, 2026.
- The Company stated that there can be no assurance it will repay or refinance its convertible note obligations in full.
- The Company is currently working to regain compliance with Nasdaq listing requirements, including the minimum bid price rule.
What to watch
- Use of approximately $3.6 million of net proceeds from the July 2026 offering, including partial repayment of outstanding convertible notes.
- The September 11, 2026 maturity of the Company’s $5.2 million convertible notes and the potential extension to December 11, 2026.
- Whether the updated Catamaran® System reduces ongoing per-procedure costs previously associated with disposable instrumentation.
- Continued surgical case volume, physician and distributor training activity, commercial expansion and rollout of the SImmetry®+ System.
- The Company’s efforts to regain compliance with Nasdaq listing requirements, including the minimum bid price rule.
Balance sheet and cash flow
- Cash and cash equivalents were $1.7 million as of June 30, 2026, compared to $3.8 million as of December 31, 2025.
- Accounts receivable, net were 1,947 (In thousands) at June 30, 2026, compared to 1,698 (In thousands) at December 31, 2025.
- Inventory was 783 (In thousands) at June 30, 2026, compared to 1,054 (In thousands) at December 31, 2025.
- Total assets were $ 9,922 (In thousands) at June 30, 2026, compared to $ 10,760 (In thousands) at December 31, 2025.
- Convertible notes were 4,332 (In thousands) at June 30, 2026.
- Total liabilities were 11,665 (In thousands) at June 30, 2026, compared to 5,720 (In thousands) at December 31, 2025.
- Total stockholders’ (deficit) equity was (1,743) (In thousands) at June 30, 2026, compared to 5,040 (In thousands) at December 31, 2025.
- The Company’s $5.2 million convertible notes mature on September 11, 2026 (extendable to December 11, 2026).
- Subsequent to quarter end in July 2026, Tenon closed a public offering with gross proceeds of $4.2 million, with net proceeds of approximately $3.6 million.
Analysis
Tenon reported strong year-over-year top-line and gross-profit growth in the second quarter. Revenue was $1.3 million, up 127% from $0.6 million, while gross profit was $0.8 million, up 232% from $0.2 million. Management attributed revenue growth primarily to a significant increase in surgical procedures and the addition of SImmetry®+ System revenue. Revenue for the six months ended June 30, 2026 was $2.7 million, an increase of 106% compared to $1.3 million in the year-ago period.
Gross margin reached 64%, compared with 43% in the second quarter of 2025, and six-month gross margin was 66%, compared with 44%. The company attributed the quarterly margin improvement to higher revenue and lower fixed costs, which increased absorption of production overhead within cost of goods sold. Management also cited growth in case volume across the Catamaran® and SImmetry®+ platforms, while the July 510(k) clearance moved certain Catamaran® instruments from disposable to reusable status, which the company expects to reduce ongoing per-procedure costs.
Operating investment rose alongside commercial activity. Operating expenses totaled $4.2 million versus $3.1 million, with sales and marketing expense of 1,869 (In thousands), research and development expense of 768 (In thousands), and general and administrative expense of 1,531 (In thousands). The company cited higher sales expenses associated with revenue, an expanded commercial team, the SImmetry®+ rollout, and increased research and development work toward future product additions. Loss from operations was (3,354) (In thousands), compared with (2,857) (In thousands).
The net loss widened to $4.1 million from $2.8 million. The filing attributed the increase largely to non-cash interest expense of $0.9 million related to amortization of original issue discount on convertible notes, partially offset by higher other income of $0.1 million related to gains on the change in fair value of the derivative liability. Cash and cash equivalents were $1.7 million at June 30, 2026, while convertible notes were 4,332 (In thousands) on the balance sheet and the company stated that its $5.2 million convertible notes mature on September 11, 2026, extendable to December 11, 2026.
After quarter end, Tenon closed a public offering with gross proceeds of $4.2 million and net proceeds of approximately $3.6 million. The company intends to use proceeds for partial repayment of convertible notes, commercial expansion, clinical research, product development and general corporate purposes, but stated there can be no assurance it will repay or refinance the notes in full. July also produced the company’s highest monthly surgical case volume to date following a 98% increase in physician and distributor training events in the first half of 2026 compared to the second half of 2025. The filing provided no quantitative financial guidance.
Management, verbatim
Revenue of $1.3 million and gross profit of $0.8 million were each the highest we have reported in a second quarter, and the 64% gross margin demonstrates that the cost structure we’ve implemented is delivering as designed. Case volume grew across both the Catamaran® and SImmetry®+ platforms, and each incremental procedure is now carrying meaningfully more profit.
Steven M. Foster, President and CEO of Tenon Medical, Inc.
Along with record case volume, July added two more building blocks. The 510(k) clearance for our updated Catamaran® System moves several instruments from disposable to reusable, which we expect will take recurring cost out of cases we perform going forward, and the $4.2 million offering we closed on July 1 lets us reduce our convertible note balance while supporting our near-term commercial build-out and clinical program. Our focus through the balance of 2026 is straightforward: accelerating our development and product launch strategies, expanding training activities, and maintaining discipline on spend.
Steven M. Foster, President and CEO of Tenon Medical, Inc.
Not in the filing
stated, not guessed- Quantitative forward revenue guidance
- Quantitative forward gross-margin guidance
- Quantitative forward operating-expense guidance
- Quantitative forward tax-rate guidance
- Prior-period outlook for comparison
- Segment revenue and segment profitability
- Non-GAAP financial measures and reconciliations
- Operating cash flow
- Free cash flow
- Capital-return activity, including share repurchases and dividends
- Quarterly tax rate
- Operating margin
- Prior-quarter comparisons for reported operating metrics
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.